Kongshanci

Kongshanci (空山慈科技, also known as KoSyne NeuroTech) is a Shanghai-based company developing a non-invasive brain-computer interface and neuromodulation platform for clinical applications . The company was co-founded by Wang Ximing (王曦明), who remains actively involved in product development . In February 2026, it completed a Pre-A round led exclusively by Yunqi Capital, following an angel round in which DaoTong Family (道彤投资) was the sole investor . The funding is directed toward core R&D, clinical translation, and global expansion of its platform . Yunqi Capital frames the "non-invasive pathway" as a more scalable direction for brain-computer interface technology as it moves from research toward real clinical value .